Peanut Allergy Risk and Your Genetics

What is peanut allergy risk?

Peanut allergy is an immune-mediated hypersensitivity reaction in which the body's immune system identifies proteins found in peanuts as threatening, triggering responses ranging from mild hives to life-threatening anaphylaxis. It affects an estimated 1–2% of the general population and is among the most common causes of severe food-induced allergic reactions. Genetic factors play a meaningful role in determining who develops this sensitivity, making peanut allergy one of the most studied food allergies from a genomic standpoint.

Research base: Robust.

The genetics behind peanut allergy risk

The genetic architecture of peanut allergy is anchored most firmly in the HLA (human leukocyte antigen) region of chromosome 6, where some of the most replicated associations in all of food allergy genetics reside. The strongest known variants for peanut allergy sit near HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB3, and HLA-DRB1 — genes encoding the alpha and beta chain subunits of HLA class II molecules.

HLA class II molecules — particularly the HLA-DQ heterodimers formed by DQα and DQβ subunits — sit on the surface of antigen-presenting cells such as dendritic cells, macrophages, and B cells. Their central function is to capture peptide fragments from ingested proteins and display those fragments to CD4+ T helper cells. The particular HLA-DQ allele a person inherits determines which peptide fragments bind and get presented — and therefore which protein fragments the immune system encounters during the process of learning tolerance or mounting reactivity.

For peanut proteins such as Ara h 1, Ara h 2, and Ara h 3, certain HLA-DQ allele combinations appear permissive for presenting peanut-derived peptides in ways that favor Th2-skewed immune responses — characterized by IgE antibody production and mast cell sensitization — rather than the tolerogenic pathways that suppress allergic reactivity. HLA-DRB1 encodes a complementary class II beta chain that works alongside the DQ molecules, and DRB1 allelic variation similarly influences how T cells respond when encountering peanut antigens.

Beyond the HLA region, genome-wide association studies have implicated additional loci. EMSY (also annotated as C11orf30) was established as a genetic risk factor for food allergy through a large multi-population GWAS and meta-analysis [2]. EMSY encodes a chromatin regulatory protein that interacts with BRCA2 and modulates gene expression through epigenetic mechanisms. Its presence at a food allergy risk locus points toward a layer of gene-regulatory biology — a finding that aligns with independent evidence from a US-children GWAS showing epigenetic mediation at peanut allergy loci [1].

Additional GWAS-identified loci near EXOC4, DLX2, and ANGPT4 have also emerged. EXOC4 encodes a component of the exocyst complex, which governs vesicular trafficking and regulated secretion — a pathway potentially relevant to how mast cells release their contents during allergic reactions. DLX2 is a transcription factor involved in developmental gene regulation and appears near immunologically relevant genomic regions in GWAS findings. ANGPT4, involved in vascular remodeling and blood vessel stabilization, may have relevance to the vascular permeability changes that characterize anaphylaxis, though the mechanistic connections for these loci remain areas of ongoing research.

What the research says

The foundational genomic evidence for peanut allergy genetics comes from three convergent lines of inquiry across independent studies and populations.

Hong et al. (2015) conducted the first large genome-wide association study focused specifically on peanut allergy in US children, identifying peanut-allergy-specific loci and uncovering evidence of epigenetic mediation at these loci [1]. This work was notable for demonstrating that peanut allergy has distinct genetic signals beyond general atopic disease, and for pointing toward epigenetic mechanisms as part of the risk architecture.

In the Hong et al. (2015) GWAS of US children, the HLA region produced the most significant genome-wide associations with peanut allergy, with HLA-related variants achieving p-values well below the genome-wide significance threshold of 5×10⁻⁸ [1].

Asai et al. (2018) extended this work through a multi-population GWAS and meta-analysis that identified new loci and formally established EMSY (C11orf30) as a genetic risk factor for food allergy [2]. The multi-population design strengthens the replication argument: associations that survive across diverse ancestries and study cohorts are considerably more robust than single-population signals.

Marenholz et al. (2017) contributed a complementary finding, identifying the SERPINB gene cluster as a susceptibility locus for food allergy through an independent GWAS [3]. While that cluster falls outside the gene set most directly tied to peanut allergy, the study adds to the cross-cohort evidence base for the genetic architecture of food allergy and reinforces the multi-locus nature of susceptibility.

Peanut allergy affects approximately 1 in 50 children in the United States, and rates have roughly doubled over the past two decades — a trend that cannot be explained by genetics alone, supporting the role of environmental and epigenetic factors working alongside inherited genetic variation.

Across these three studies, the HLA associations represent the most replicated genetic findings in food allergy research, with convergent signals appearing across US, European, and multi-ancestry cohorts.

How peanut allergy risk affects you

A higher genetic score on this trait reflects a stronger accumulation of variants that have been associated with peanut allergy susceptibility across population-level research. Because higher scores correspond to greater genetic signal in the direction of risk, this is a trait where the score is informative about relative population standing — not a personal prediction of whether allergy is present or will develop.

Genetics is one contributing factor among several. Environmental exposures during early life, timing of dietary introduction, gut microbiome composition, and concurrent atopic conditions (eczema, asthma, hay fever) all interact with inherited genetic variation to shape whether any individual develops clinical peanut allergy. Many people with elevated genetic signals never develop allergy, and peanut allergy occurs in people without elevated genetic risk as well.

The HLA region associations operate through the biology described above: variation in which HLA-DQ and HLA-DR alleles a person carries influences the immune system's probability of mounting sensitization versus tolerance when exposed to peanut proteins. This is a probabilistic influence at the population level, not a deterministic mechanism at the individual level.

For individuals who do have clinical peanut allergy, the reactions can span a wide spectrum. Mild reactions include hives, itching, or gastrointestinal discomfort. Severe reactions — anaphylaxis — involve rapid-onset systemic responses affecting the respiratory tract, cardiovascular system, and skin simultaneously, and constitute a medical emergency.

Working with your peanut allergy result

A genetic result from ExomeDNA for peanut allergy risk is not a clinical allergy test. It does not confirm that allergy is present, and a lower score does not rule out allergy. Formal clinical evaluation — including skin prick testing and, where appropriate, supervised oral food challenges — remains the standard method for confirming peanut allergy.

For individuals with questions about their actual allergy status, referral to a board-certified allergist is the appropriate next step. Genetic information can be one piece of context to bring into that conversation, but it does not substitute for clinical assessment.

For individuals with confirmed peanut allergy, evidence-based management includes:

Strict allergen avoidance: Reading food labels carefully, communicating with food preparers about cross-contact risk, and avoiding shared cooking equipment or facilities are the foundations of day-to-day safety.

Emergency epinephrine: Anyone with a history of anaphylaxis or a high-risk profile should carry an epinephrine auto-injector (such as an EpiPen) at all times. Epinephrine is the first-line treatment for anaphylaxis and should be administered promptly if a severe reaction occurs.

Oral immunotherapy (OIT): Palforzia (AR101) is an FDA-approved oral immunotherapy product for peanut allergy in children and adolescents. OIT involves gradually increasing exposure to peanut protein under medical supervision, with the goal of raising the threshold for reaction. It does not eliminate allergy but can meaningfully improve the safety margin against accidental exposures.

Early introduction: The LEAP trial (Learning Early About Peanut Allergy) demonstrated that early introduction of peanut products in high-risk infants — those with eczema or egg allergy — significantly reduces the risk of developing peanut allergy by age five. This finding has shaped clinical guidelines around early peanut introduction rather than avoidance in infancy.

Cross-reactive considerations: Tree nuts and certain legumes share protein epitopes with peanuts (peanuts are technically legumes). Some individuals with peanut allergy also react to tree nuts or other legumes, though the degree of cross-reactivity varies and an allergist can help clarify individual risk.

This page contains general information only. For personal health decisions, consult a qualified clinician.

Related traits and genes

Peanut allergy does not exist in isolation — it sits within a broader landscape of atopic and immune-mediated conditions that share genetic architecture and biological pathways.

Allergic asthma risk shares HLA region associations and Th2 immune pathway biology with peanut allergy. Individuals with peanut allergy have elevated rates of comorbid asthma, and the two conditions frequently co-occur as part of the atopic march.

Eczema risk is another atopic condition with overlapping genetic signals. Eczema (atopic dermatitis) is a known risk factor for the subsequent development of food allergy, particularly peanut allergy — the so-called dual allergen exposure hypothesis proposes that sensitization can occur through disrupted skin barrier exposure before oral tolerance is established.

Hay fever risk (allergic rhinitis) rounds out the classic atopic triad. The same Th2 immune environment that predisposes to peanut allergy also underlies seasonal allergic rhinitis.

Within the immune biology space, the inflammatory response and immune function traits capture upstream regulatory pathways that influence how readily the immune system mounts inflammatory and IgE-mediated reactions.

The HLA genes central to peanut allergy genetics — HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB3, HLA-DRB1 — are also implicated across a wide range of immune and autoimmune conditions, reflecting the central role of antigen presentation in virtually all adaptive immune responses.

Frequently asked questions

Q: Is peanut allergy hereditary? A: Peanut allergy has a meaningful genetic component. Twin studies suggest that concordance is substantially higher in identical twins than fraternal twins, pointing toward inherited factors. Multiple genome-wide association studies have identified specific genomic regions — most prominently in the HLA class II area — associated with peanut allergy susceptibility. However, inheritance is not simple or deterministic: having genetic variants associated with elevated risk does not guarantee allergy will develop, and environmental exposures during early life play an important role alongside genetics.

Q: What does the HLA region have to do with peanut allergy? A: HLA class II molecules — including those encoded by HLA-DQA1, HLA-DQB1, and HLA-DRB1 — are responsible for presenting protein fragments to the immune system's T helper cells. The specific HLA alleles a person carries determine which protein fragments get displayed and how the immune system responds. For peanut proteins, certain HLA-DQ allele combinations appear associated at the population level with greater likelihood of mounting sensitizing responses rather than tolerogenic ones. This is why HLA region variants consistently emerge as the strongest genetic signals in peanut allergy GWAS studies.

Q: What is EMSY and why does it appear in peanut allergy genetics? A: EMSY encodes a chromatin-regulatory protein involved in epigenetic control of gene expression. It was established as a genetic risk factor for food allergy in a multi-population GWAS published in 2018 [2]. The appearance of an epigenetic regulator at a food allergy risk locus fits with separate evidence showing epigenetic mediation at peanut allergy loci [1], suggesting that gene expression programs — not just underlying DNA sequence — contribute to allergy risk architecture.

Q: Does a high genetic score mean I have peanut allergy? A: No. A higher score reflects a greater accumulation of genetic variants associated with peanut allergy susceptibility in population research. Many people with elevated genetic signals do not develop clinical allergy, and peanut allergy can occur in people without elevated genetic risk. This result is not a clinical allergy test and cannot confirm or rule out allergy. Those with questions about peanut allergy status can be evaluated by a board-certified allergist through appropriate testing including skin prick tests and supervised oral food challenges.

Q: Can peanut allergy be treated? A: Yes — management options have advanced substantially. Strict allergen avoidance and carrying emergency epinephrine remain the foundation of safety for people with confirmed allergy. FDA-approved oral immunotherapy (Palforzia/AR101) is available for eligible patients and can raise the threshold for allergic reaction through gradual supervised desensitization. OIT does not eliminate the allergy but provides a meaningful safety buffer against accidental exposure. An allergist can determine whether OIT is appropriate for a given individual.

Q: What is the LEAP trial finding about early peanut introduction? A: The LEAP (Learning Early About Peanut Allergy) trial was a landmark clinical study showing that introducing peanut products early — starting in the first year of life — in high-risk infants (those with eczema or egg allergy) reduced the rate of peanut allergy development by approximately 80% compared to avoidance. This finding reversed earlier clinical guidance that had recommended peanut avoidance in infancy and is now reflected in allergy guidelines recommending early introduction for high-risk infants. It also illustrates how environmental timing interacts with genetic predisposition: genetic risk does not operate independently of what happens during early immune development.

By the ExomeDNA Research Team

This page contains general information only. For personal health decisions, consult a qualified clinician.

References

1. Hong X et al. (2015). Genome-wide association study identifies peanut allergy-specific loci and evidence of epigenetic mediation in US children. Nature Communications. PMID: 25710614. DOI: 10.1038/ncomms7304
2. Asai Y et al. (2018). Genome-wide association study and meta-analysis in multiple populations identifies new loci for peanut allergy and establishes C11orf30/EMSY as a genetic risk factor for food allergy. Journal of Allergy and Clinical Immunology. PMID: 29030101. DOI: 10.1016/j.jaci.2017.09.015
3. Marenholz I et al. (2017). Genome-wide association study identifies the SERPINB gene cluster as a susceptibility locus for food allergy. Nature Communications. PMID: 29051540. DOI: 10.1038/s41467-017-01220-0

Data sources: GWAS associations curated from published literature (PMIDs above). Gene annotations from NCBI Gene.

ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance. Genetic results do not substitute for professional clinical evaluation.